| Title |
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, May 2019
|
| DOI | 10.1007/s00280-019-03852-z |
| Pubmed ID | |
| Authors |
Dan Lu, Chunze Li, Matthew Riggs, Daniel Polhamus, Jonathan French, Priya Agarwal, Shang-Chiung Chen, Shweta Vadhavkar, Monika Patre, Alexander Strasak, Angelica Quartino, Jin Yan Jin, Sandhya Girish |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Japan | 1 | 33% |
| Greece | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 20% |
| Student > Master | 7 | 17% |
| Student > Postgraduate | 3 | 7% |
| Other | 2 | 5% |
| Student > Bachelor | 2 | 5% |
| Other | 6 | 15% |
| Unknown | 13 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
| Chemistry | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 7 | 17% |
| Unknown | 15 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 June 2019.
All research outputs
#14,599,162
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#1,760
of 2,501 outputs
Outputs of similar age
#189,155
of 353,366 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#6
of 40 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,366 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.